Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002318769 | SCV000850138 | uncertain significance | Inborn genetic diseases | 2024-10-04 | criteria provided, single submitter | clinical testing | The c.1704G>A (p.M568I) alteration is located in exon 11 (coding exon 9) of the SATB2 gene. This alteration results from a G to A substitution at nucleotide position 1704, causing the methionine (M) at amino acid position 568 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000824230 | SCV000965119 | benign | Chromosome 2q32-q33 deletion syndrome | 2023-11-19 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000824230 | SCV003820665 | uncertain significance | Chromosome 2q32-q33 deletion syndrome | 2021-11-11 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003437415 | SCV004148382 | uncertain significance | not provided | 2023-05-01 | criteria provided, single submitter | clinical testing | SATB2: PP2 |